Cargando…

A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib

Lenvatinib is an oral tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, as well as platelet-derived growth factor receptor α, RET, and KIT. At present, lenvatinib is used in the treatment of thyroid cancer and renal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura-Tsuchiya, Reiko, Sasaki, Eisaku, Nakamura, Izumi, Suzuki, Satoshi, Kawana, Satoshi, Okouchi, Chiyo, Fukushima, Toshihiko, Hashimoto, Yuko, Suzuki, Shinichi, Saji, Shigehira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836208/ https://www.ncbi.nlm.nih.gov/pubmed/29515414 http://dx.doi.org/10.1159/000486569

Ejemplares similares

Impact of body mass index on breast cancer in accordance with the life-stage of women
por: Suzuki, Reiko, et al.
Publicado: (2012)

Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib
por: Saito, Kei, et al.
Publicado: (2020)

Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
por: Kuwahara, Ai, et al.
Publicado: (2020)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
por: Furuto, Yoshitaka, et al.
Publicado: (2018)

Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings
por: Sasaki, Ryu, et al.
Publicado: (2019)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis
por: Muraishi, Nozomu, et al.
Publicado: (2023)

Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab
por: Natori, Yutaka, et al.
Publicado: (2020)

Time-dependent changes in FT4 and FT3 levels measured using mass spectrometry after an acute ingestion of excess levothyroxine in a case with hypothyroidism
por: Ito, Yuko, et al.
Publicado: (2020)

A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

E3 Ubiquitin Ligase NEDD4 Affects Estrogen Receptor α Expression and the Prognosis of Patients with Hormone Receptor-Positive Breast Cancer
por: Natori, Yutaka, et al.
Publicado: (2023)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

SARS: responding to an unknown virus
por: Tambyah, P. A.
Publicado: (2004)

Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum
por: Yanagihara, Toyoshi, et al.
Publicado: (2021)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report
por: Kohya, Risako, et al.
Publicado: (2022)

A rare case of recurrent ovarian cancer with TPM3-NTRK1 gene rearrangement: A case report
por: Endo, Yuta, et al.
Publicado: (2022)

Role of MDM2 Overexpression in Doxorubicin Resistance of Breast Carcinoma
por: Suzuki, Akio, et al.
Publicado: (1998)

Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment
por: Muraishi, Nozomu, et al.
Publicado: (2021)

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
por: Nakamichi, Shinji, et al.
Publicado: (2015)

Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
por: Komiyama, Satoshi, et al.
Publicado: (2020)

Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma
por: Suzuki, Naomi, et al.
Publicado: (2020)

Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β
por: Murakami-Nishimagi, Yuko, et al.
Publicado: (2023)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
por: Masaki, Chie, et al.
Publicado: (2021)

Thoracic extradural malignant melanoma with unknown primary
por: Takagi, Yasutaka, et al.
Publicado: (2020)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Effective School Actions for Mitigating Seasonal Influenza Outbreaks in Niigata, Japan
por: Sugisaki, Koshu, et al.
Publicado: (2013)

Lopinavir inhibits insulin signaling by promoting protein tyrosine phosphatase 1B expression
por: KITAZAWA, TAKATOSHI, et al.
Publicado: (2014)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib
por: Decraecker, Marie, et al.
Publicado: (2021)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
por: Ueno, Makoto, et al.
Publicado: (2020)

Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma: A case report
por: Matsumoto, Kinnosuke, et al.
Publicado: (2022)

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib
por: Suzuki, Shinya, et al.
Publicado: (2020)

Case Report: Corpus Callosotomy in a Cat With Drug-Resistant Epilepsy of Unknown Cause
por: Hasegawa, Daisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ibf7ict61r7e94rtq0v9feu2k